A modified (lower-dose) of XELIRI with or without bevacizumab may be an alternative second-line chemotherapy treatment for patients with metastatic colorectal cancer (CRC), according to results of the noninferiority phase III AXEPT* trial.
An initial strategy of 1-year romosozumab followed by alendronate is superior over alendronate alone in reducing new vertebral fractures in postmenopausal women with osteoporosis at high risk for fracture, according to the ARCH* study.
Cyclosporine is as effective as infliximab in patients with steroid-refractory acute severe ulcerative colitis, having a similar colectomy rate but reduced incidence of serious adverse events, a study from Spain has shown.
Diclofenac reduces the use of antibiotics in women with uncomplicated lower urinary tract infection (UTI) but remains less effective than norfloxacin for symptom relief of UTI, according to a recent study. In addition, diclofenac appears to be associated with an elevated risk of pyelonephritis.
Pearl Toh spoke with Dr Teh Ming Ming, senior consultant at the Department of Endocrinology, Singapore General Hospital (SGH), on the major challenges of diagnosing and managing diabetes in primary care, in conjunction with the World Diabetes Day on 14 November. Awareness of the symptoms of diabetes is important, and patients should be empowered to manage their conditions.
New drug applications approved by US FDA as of 1 - 15 June 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.